RE:New Press Release - Early Warning Report Magna Mining Inc. Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation commented: “We are extremely pleased to learn that TauRx was successful in its efforts to secure the necessary funding to undergo regulatory submissions of its promising Alzheimer’s treatment in 2023. We wish the company well in these efforts and look forward to its presentation of results of its LUCIDITY trial at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco on November 30th.”
Dundee holds 1,015,008 shares in TauRx, representing a 3.2% interest in the company. Dundee Corporation determined that the fair value of its investment in TauRx at September 30, 2022, was $38.5 million, or USD$27.69 per share.